significant pericardial and pleural effusion (Fig. 2) , and confirming the distal obstruction of the biliary tree. An endoscopic retrograde cholangio-pancreatography was performed to place a stent, with resolution of the biliary obstruction. However, 2 days after, worsening dispnoea occurred, and a cardiac tamponade was diagnosed, thus the patient underwent to urgent therapeutic pericardiocentesis. In few days the patient showed a marked clinical improvement, thus he underwent a biopsy of the mediastinic mass; at the histology a lymphoblastic T-lymphoma was diagnosed.
The patient was treated with chemotherapy (Idarubicine, Vincristine, Asparaginase and corticosteroids), but unfortunately died 10 days after because of an Acinetobacter baumanii pneumonia.
Although recently the SONIC 2 study showed an advantage of combo therapy compared to monotherapy with azathioprine or infliximab in patient with active CD, the current european and Italian guidelines suggest that thiopurines could be add in the naive patient, but the long-term combination of azathioprine or 6-mercaptopurine and anti-TNF therapy is best avoided in young people because of the risk of hepatosplenic T-cell lymphoma. 3, 4 In this case the indication to the combo therapy was not justified by the Figure 1. clinical activity of CD, but only by the diagnosis of asymptomatic osteoporosis. Our opinion is that the combo therapy exposes to a risk of adverse events, and in any therapeutic decision the possible benefits must be weighted against possible risks, as in the case reported, where there was not a strong indication for this aggressive treatment.
Thus, when we decide to treat active CD with combo therapy we should consider if we are willing to take a risk of serious adverse events, although rare, for a doubtful benefit.
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